cyrilzakka/clinical-trials huggingface dataset:
Blockbuster LMA Versus Baska Mask in Laparoscopic Cholecystectomy

This study aimed to compare the performance and safety profiles of two supraglottic airway devices (SADs), the Blockbuster laryngeal mask airway (LMA) and the Baska Mask (BM), in patients underwent laparoscopic cholecystectomy (LC).

Laparoscopic surgery has become increasingly prevalent across numerous surgical disciplines due to the well-established benefits it offers over traditional open procedures. Laparoscopic cholecystectomy (LC), the surgical removal of the gallbladder, stands out as one of the most frequently performed laparoscopic operations worldwide.

Supraglottic airway devices (SADs) play a crucial role in airway management algorithms, serving as viable alternatives in both anticipated and unanticipated difficult airway situations.

The laryngeal mask airway (LMA) can be utilized to establish a routine airway during general anesthesia or, less frequently, as a conduit for tracheal intubation. Newer, improved LMA designs incorporate cuffs that provide higher sealing pressures than classic LMAs, while also allowing for the venting of gastric contents through a dedicated drain tube.

The Baska Mask (BM), a second-generation SAD, features a non-inflatable cuff that is continuous with the airway channel, thereby inflating with positive pressure ventilation to improve cuff seal.

Eligibility Criteria:
Inclusion Criteria:

* Aged 18-60 years
* Both sexes.
* American Society of Anesthesiologists (ASA) physical status I-II.
* Scheduled for elective LC under general anesthesia.

Exclusion Criteria:

* Anticipated difficult airway.
* Renal dysfunction.
* Hiatus hernia.
* Obesity.
* Pregnancy.
* Patients taking rate-controlling medications, steroids, opioids, or regular antacids.
Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection

The two main cytomegalovirus (CMV) prevention strategies are prophylaxis and preemptive therapy. Prophylaxis effectively prevents CMV infection after solid organ transplantation (SOT), but is associated with high rates of neutropenia and late onset of post-prophylactic disease. In contrast, preemptive therapy has the advantage of leading to lower rates of CMV disease and robust humoral and T-cell responses. It is widely used in hematopoietic cell transplant recipients, but is rarely used after solid organ transplant recipients due to logistical considerations.

Oral Letermovir for 84 days is effective in the prophylaxis of CMV infection in high-risk kidney transplant recipients. Oral Letermovir for 84 days, is associated with a lower incidence of CMV infection in high-risk high-risk kidney transplant recipients. In addition, the use of Letermovir is safe and associated with a low incidence of CMV syndrome or disease up to 6 months after after kidney transplantation. Finally, prophylaxis with Letermovir is associated with a lower incidence of discontinuation of immunosuppressive drugs, reducing the risk of of clinical and subclinical acute rejection

Eligibility Criteria:
Inclusion Criteria:

* Kidney transplant or re-transplant recipients, aged ≥18 years;
* Undergoing induction therapy with anti-thymocyte globulin;
* Receiving maintenance treatment with Tacrolimus, Mycophenolate and Prednisone;
* Positive CMV serology for donor and recipient.

Exclusion Criteria:

* CMV serology positive for donor and negative for recipient;
* Multiple organ recipients, or other organs
Evaluation of Ureteral Stents in the Management of Stone Disease

A thin tube, called a ureteral stent, is inserted into the ureter and is commonly used as treatment of urinary stone disease. Stents are designed to help provide drainage of the kidney in the setting of an obstructing stone, or postoperative swelling of the ureter. Though their presence is only temporary, stents are associated with a significant amount of patient discomfort and bother, which can negatively impact overall satisfaction. Over the past decades, there have been refinements in stent technology and usage philosophy. Smaller and softer stents are now available for use in patients, though studies evaluating the relative benefits have been conflicting. The investigators aim to evaluate the effect of stent size and composition upon outcomes after the treatment of stone disease, including patient comfort and satisfaction.


Eligibility Criteria:
Inclusion Criteria:

1. Over 18 years of age and willing and able to provide informed consent
2. Patients with current urinary stone disease, undergoing any of the following procedures:

   * cystoscopy with stent placement
   * ureteroscopy with intracorporeal lithotripsy

Exclusion Criteria:

1. Patients with compromised urinary tract due to cancer (e.g. bladder tumor, ureteral obstruction from non-GU malignancy)
2. Patients requiring bilateral surgical stone management procedure
3. Patients with any single stone exceeding 1.5 cm
4. Patients with severe concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would render the patient inappropriate for enrollment
5. Any patient who is on anticholinergic medication at baseline
Melatonin for Post Operative Delirium Prevention in Elderly Patients

The present study will evaluate the role of melatonin prophylaxis in delirium prevention in elderly patients undergoing colorectal procedures.

This study is a prospective randomised double-blind placebo-controlled trial. Patients who meet the criteria for inclusion/exclusion will be evaluated. Melatonin tablets will be administered as a premedication to patients in the melatonin group. Patients in the control group will be given placebo tablets as a premedication. Fentanyl 1ug/kg and propofol 1-2 mg/kg will be used to induce anaesthesia. Atracurium 0.5 mg/kg will be used for the facilitation of endotracheal intubation. Isoflurane will be used to maintain anaesthesia and the depth of anaesthesia will be adjusted by a Bispectral index monitor. Postoperatively, the patients will be monitored for the development of delirium.

Eligibility Criteria:
Inclusion Criteria:

* American Society of Anaesthesiologists (ASA) I to III physical status
* Elective colorectal procedures

Exclusion Criteria:

* Allergy to the research drugs,
* Patients who have vision or hearing impairment
* History of cerebral disorders
* Uncorrected acid-base, fluid, and electrolyte abnormalities
* History of central nervous system function affecting drugs.
* Chronic sedative-hypnotic administration at least one month prior to surgery
* Alcohol abuse
* Patients with recorded preoperative nursing delirium screening score ≥ 2.
The Study of CCTM and Common Diseases

This study aimed to explore the associations between constitutions of traditional Chinese medicine (TCM) and common disease (CD). A large-scale, community-based, cross-sectional study was performed to investigate the associations. A total of 3748 participants were available for analysis in this study. The assessment of constitution of TCM was based on recommendations of Association Chinese Medicine in China. In this study, the diagnosis of CD was based on self-reported medical history. The associations were analyzed using univariate and multivariable logistic regression (MLR).

This study aimed to explore the associations between constitutions of traditional Chinese medicine (TCM) and common disease (CD). A large-scale, community-based, cross-sectional study was performed to investigate the associations. A total of 3748 participants were available for analysis in this study. The assessment of constitution of TCM was based on recommendations of Association Chinese Medicine in China. In this study, the diagnosis of CD was based on self-reported medical history. The associations were analyzed using univariate and multivariable logistic regression (MLR).

Eligibility Criteria:
Inclusion Criteria:

* Participants aged 30-90 years were recruited from rural and urban communities in Shanghai.

Exclusion Criteria:

* severity renal and liver function abnormal and pregnant woman
Mesenchymal Stem Cells Derived Exosomes in Skin Rejuvenation

Aging is a natural and complex process. The effect of environmental factors, genetics on the body eventually leads to damage in different ways. Exosomes are present in almost all body fluids, such as synovial fluid and blood. Exosomes and microvesicles are very efficient mediators of cell-to-cell communication by transferring their specific cargo to recipient cells; for example, exosomes are involved in the delivery of genetic materials, causing epigenetic modifications in the target cells .The applications of MSC-derived exosomes have more effect in cutaneous regeneration by collagen stimulation.The basic biology of exosomes indicates that MSC-exosomes may contain MSC-specific components to exert specific effects on recipient cells, which are somewhat equivalent to the regenerative effects of MSCs. This study aims to slow down the aging process of the skin by using exosome.

Skin aging is a complex biological process that can be classified into extrinsic or intrinsic aging. Intrinsic aging is an intrinsic degradation process that is caused by a decrease in the proliferation capacity leading to cell senescence. Angiogenesis is essential in various physiological processes, including wound healing and skin tissue regeneration. Literature reviews show that exosomes derived from human umbilical cord blood mesenchymal stem cells can cause Collagen stimulation and reduction of oxidative stress, WNT/βcatenin pathway signaling in the initial stages of causes the regeneration of skin damage . This study aims to slow down the aging process of the skin by using exosome.

Eligibility Criteria:
Inclusion Criteria:

* females
* Ages 35-65
* Patients of all racial and ethnic origins
* Patients of all undergoing facial rejuvenation

Exclusion Criteria:

* Female patients in pregnancy or menstrual period
* Patients undergoing facial rejuvenation using other methods including Botox injections, chemical peels, face lifts and others
* Patients using blood thinners, aspirin and hormone, that cannot be stopped
* Patients suffering with severe organic disease, such as coronary heart disease, hypertension, diabetes, lung dysfunction and so on
* Patients suffering with mental disease, and acute or chronic infectious diseases
Alcohol Addiction and Otorhinolaryngology Cancer

The aim of the study is to compare the hospitalisation period in ORL surgery for two groups of patients. One of them will be treated for alcohol addiction to weaning them before the surgery ORL. The other group will be treated with usual methods.

Alcohol, associated or not associated with tobacco, is known to increase the incidence of ORL cancer. So, in fact many patients perform their ORL surgery operation in spite of their alcohol addiction.

Many studies showed that a post surgery weaning syndrome increases morbidity and mortality.

So our study will focuses on the benefits of pre surgery medical weaning program.

The protocol is an open randomised, prospective study. The patient will be divided in two groups. In one hand, the first group is designed as "treated" will get alcohol weaning in the hospital alcohol department. The patient will be hospitalized during one week before the ORL surgery.

During this hospitalisation, the patient will receive medicinal treatment, medical follow-up and psychological counselling.

In the other hand, the second group designed as "control group" will be hospitalized directly in ORL surgery department. The patient will be received a treatment for alcohol weaning according to their symptom.

After their hospitalisation, the treated group will be followed-up regularly for their alcohol addiction either in support group or in individual counselling. The control group will be followed-up with the usual method in the ORL surgery department.

The expected result is to improve the care for patients with alcohol addiction and who must have an ORL surgery reducing the hospitalisation duration, the level of post operative complication and increasing the abstinence level. 115 patients will be included in this study.

Eligibility Criteria:
Inclusion Criteria:

* Age 18-80 years, male or female
* Clinically and histologically verified ORL cancer required surgery
* Patient with alcohol addiction
* Men must consume 21 glasses of wine a week
* Women must consume 14 glasses of wine a week
* CPAM affiliation
* Able to give written informed consent to participate in the study

Exclusion Criteria:

* Inability to give informed consent
* Patient with regulatory authority or private patient freedom
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.

The primary purpose of this study is to determine whether sumanirole is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease.


Eligibility Criteria:
Inclusion Criteria:

Parkinson's disease of less than 7 years duration

Modified Hoehn and Yahr Scale Stages 1 through 3.

Age greater than or equal to 30 years old.

Men or women (women of childbearing potential must have a negative pregnancy test at screen) and both must use adequate contraceptive methods.

Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

Atypical Parkinson's disease syndromes due to drugs, metabolic disorders, encephalitis, or degenerative diseases.

Levodopa received for 1-year accumulated interval in the last two years.

Dopamine agonist medications or catechol-o-methyl transferase inhibitors in the 30 days prior to baseline.

Unstable dose regimes of hypnotics, anxiolytics or antidepressants

Dementia

History of stereotaxic brain surgery, psychosis or active epilepsy within past year.

Participation in clinical trial within the previous 30 days.

Malignant melanoma or history of melanoma

Significant medical or pshychiatric condition.
Lymphoproliferative Disorders After Diagnosis of Childhood Acute Lymphoblastic Leukemia/Lymphoma

Lymphoproliferative disorders (LPD) are a major cause of morbidity and mortality in immunodeficient patients. There have been isolated case reports of patients with childhood ALL who developed LPD after ALL diagnosis, without undergoing stem cell transplantation, but data regarding such cases are limited. We propose here an international collaboration, to form a comprehensive database of children who developed LPD after diagnosis of acute lymphoblastic leukemia/lymphoma

Lymphoproliferative disorders (LPD) are a major cause of morbidity and mortality in immunodeficient patients. These disorders have been extensively described in the post-transplant setting, ie after hematopoietic stem cell (SCT) or solid organ (SOT) transplant. However, since the 1980's, there have been isolated case reports of patients with childhood ALL, who developed LPD after diagnosis of ALL, without undergoing SCT. Comprehensive information is unavailable regarding the prevalence, clinical manifestations, treatment, outcome and pathogenesis of such disorders in this setting. We propose here an international collaboration, to form a comprehensive database of children who developed LPD during the treatment of acute lymphoblastic leukemia/lymphoma (ALL/LBL).

Information will be collected in a de-identified fashion regarding patient characteristics, leukemia and LPD characteristics, treatment and outcome. The aims of this retrospective study are:

1. To build a database of children who developed LPD after diagnosis of ALL/LBL
2. To investigate the characteristics and outcome of this disorder

Eligibility Criteria:
Inclusion Criteria:

* Children and young adults treated for acute lymphoblasticleukemia/lymphoma who developed LPD after ALL/LBL diagnosis

Exclusion Criteria:

* age\>30 years
Registry of Right-to-left Shunt Detection by Contrast-enhanced Transcranial Doppler in Chinese Population

The purpose of the study is to evaluate the prevalence and extent of right-to-left shunt (RLS) in Chinese migraineurs, and the morbidity of silent cerebral infarction in migraineurs.

This is a prospective multicenter study of Chinese population. Participants (normal individuals without migraine and migraineurs) are included after standardized diagnostic procedures (TCD and c-TCD). For migraineurs with large RLS further examinations (c-TTE and brain MRI) are required. Up to 10 study sites nationwide will be needed to recruit the planned participant population during a 1-year period.

The information of each participants will be registered, including basic facts, the longitudinal headache history, frequency, location, quality, intensity, duration, accompanied symptoms, precipitating and exacerbating factors, with or without aura, MIDAS and HIT-6 questionnaire.

Eligibility Criteria:
Inclusion Criteria:

* For group 1: Normal healthy individual without migraine.
* For group 2: Clinical history of migraine diagnosed by a neurologist according to the International Classification of Headache Disorders.

Exclusion Criteria:

* Subjects with stenotic intracranial or extracranial arteries or intracranial abnormalities diagnosed with TCD.
Effects of Exercise in Patients With Coronary Artery Disease Aged 80 Years or Older

The purpose of this study is to investigate the effects of exercise for patients with coronary artery disease (CAD) aged 80 years and older, with special reference to maximum aerobic capacity, muscle endurance, physical functioning, level of physical activity, health related quality of life, anxiety, depression and endothelial function, compared to a control group.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of acute coronary artery disease
* Aged 80 years or older

Exclusion Criteria:

* Inability to understand or speak the Swedish language
* Serious physical or psychological disease interfering with participation in an exercise intervention
* Patients are already exercising three times or more/week
CARE: Cancer Risk Perception and Women of Color

This study examines patient understanding of current and lifetime risk for breast cancer in women of color from diverse racial and ethnic backgrounds.

PRIMARY OBJECTIVES:

I. Examine the association between BC risk factors and BC risk perceptions among younger Black and Hispanic women and explore differences in associations by race and ethnicity (Black Hispanic, Black, Hispanic).

II. Explore how younger Black and Hispanic women conceptualize and formulate their risk for BC and to explore the relationship between risk perceptions and risk-reduction strategies.

OUTLINE: This is an observational study.

Patients complete a survey and may participate in an interview on study.

Eligibility Criteria:
Inclusion Criteria:

* Self-identify as female
* Between the ages of 18 and 50
* No medical history of breast cancer

Exclusion Criteria:

* Unable to understand or comprehend English or Spanish
Chorioretinal Vascularization and Electrophysiological Changes After Carotid Revascularization

The aim of the study is to evaluate changes in retinal function by means of electro-functional examinations of the retina and to associate them with any changes in chorioretinal vascular density occurring in the ipsilateral eye after carotid revascularization surgery.


Eligibility Criteria:
Inclusion Criteria:

* age \>18 years old
* Carotid stenosis diagnosis with indication to perform carotid endarterectomy
* informed consent form signing

Exclusion Criteria:

* age \<18 years old
* recurrent intraocular inflammation
* retinal disease
* optic neuropathy, optic nerve drusen, opacity of the dioptric means in the pre- or post-operative period that prevents the acquisition of high-resolution images
* unstable fixation
* spheric refractive error \> +/- 6 D spheric and/or +/- 3 D cylinder
* history of prior ocular surgery
* refusal of signing informed consent form
Maxillary Molar Distalization Supported by Mini-implants With the Advanced Molar Distalization Appliance (Amda®)

The aim of this randomized controlled clinical trial is to evaluate the dentoalveolar and skeletal treatment effects of the AMDA when used for distalization of the maxillary first molars in patients with Class II malocclusion in the permanent dentition.

The primary aim is to evaluate two different treatment groups from initiation of treatment up until completion of maxillary molar distalization of:

* Group I: patients treated with amda®
* Group II: patients treated with buccal mini-implants

More specifically to evaluate the efficiency of the AMDA using lateral cephalograms and digital 3D model casts of the patients under investigation at the following time points:

* point T0: baseline data - before initiation of the treatment
* point T1: immediately after distalization (8-12 months)

Eligibility Criteria:
Inclusion Criteria:

* All patients to have permanent dentition
* with or without the 2nd molar erupted
* bilateral Class II molar relationships (a quarter to 1 molar cusp).

Exclusion Criteria:

* Past orthodontic treatment
* crossbites,
* severe carious lesions,
* poor oral hygiene,
* mobility of the maxillary first molars,
* anterior open bites,
* vertical growth pattern,
* tongue habits.
Controlling and Lowering Blood Pressure With The MOBIUS HD™ (CALM-FIM_EUR)

To evaluate the safety and performance of the MobiusHD system in subjects with resistant hypertension.

This is an open-label, multicenter, first-in-man clinical trial to be conducted in Europe. Eligible subjects with stage 2 resistant systemic arterial hypertension currently being treated with a minimum of three (3) anti-hypertensive drugs, who consent to study participation will be assigned to treatment with the MobiusHD system.

Potential study participants will be consented and then screened at two (2) baseline visits beginning at least 30 days prior to MobiusHD placement. Qualified patients will undergo placement of the MobiusHD under angiographic visualization, and will then be followed for 36 months.

Eligibility Criteria:
Inclusion Criteria:

* Office cuff SBP ≥ 160 mmHg measured per protocol instructions following at least one (1) month of maximally tolerated therapy with at least three (3) anti-hypertensive medications, of which at least one (1) must be a diuretic unless patient has history of intolerance, ineffectiveness or contraindications.

Exclusion Criteria:

* Known or clinically suspected baroreflex failure or autonomic neuropathy